Appendix 4D Financial Report for half-year to 30th June 2019
Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June 2019.
Appendix 3B – Issue of shares under Share Purchase Plan
Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan (SPP).
Telix Pharmaceuticals Announces Results of Successful SPP
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6 million.
Telix Pharmaceuticals Annual Report 2018
Telix Pharmaceuticals Limited is pleased to provide its Annual Report 2018.
Telix Pharmaceuticals Ltd Detailed Program Update January 2019
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January 2019.
Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.
Telix Pharmaceuticals Launches $50M Underwritten Initial Public Offering
Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50 million.
Telix Pharmaceuticals files $50M Underwritten Initial Public Offering
Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public Offering.
Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology (VisAcT).
Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand
Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd (Cyclotek).